Doug Paul talks about the challenges that orphan drugs face after regulatory approval.
Read More
Too often discussions about the price of orphan drugs focus on the most basic unit of measure: a therapy exchanged for currency.
Time has run short for taking a comprehensive look at one of the most difficult topics in the industry—how best to regulate compassion.
Doug Paul dissects the challenges and future of the orphan drug market.
In this series, David Lapidus talks with members of the Rare Collective to debunk common myths surrounding rare diseases. In this post, Chris Smith flips the script on David for his thoughts, and David talks about the challenges of estimating a treatable population.
In this series, David Lapidus talks with members of the Rare Collective to debunk common myths surrounding rare diseases. In this post, Jean Campbell talks about when orphan drug companies should begin interacting with the patient community.
In this series, David Lapidus talks with members of the Rare Collective to debunk common myths surrounding rare diseases. In this post, Chris Smith shares how our understanding of rare disease is evolving, and why it may be a misleading term.
RARE COLLECTIVE® is a trademark of Rare Collective, LLC. 